JP2016501222A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501222A5
JP2016501222A5 JP2015545170A JP2015545170A JP2016501222A5 JP 2016501222 A5 JP2016501222 A5 JP 2016501222A5 JP 2015545170 A JP2015545170 A JP 2015545170A JP 2015545170 A JP2015545170 A JP 2015545170A JP 2016501222 A5 JP2016501222 A5 JP 2016501222A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutical combination
pharmaceutically acceptable
inhibitor compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545170A
Other languages
English (en)
Japanese (ja)
Other versions
JP6437444B2 (ja
JP2016501222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/071852 external-priority patent/WO2014085381A1/en
Publication of JP2016501222A publication Critical patent/JP2016501222A/ja
Publication of JP2016501222A5 publication Critical patent/JP2016501222A5/ja
Application granted granted Critical
Publication of JP6437444B2 publication Critical patent/JP6437444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545170A 2012-11-29 2013-11-26 医薬的組合せ Active JP6437444B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US61/731,174 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US61/731,555 2012-11-30
US201361755520P 2013-01-23 2013-01-23
US61/755,520 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
JP2016501222A JP2016501222A (ja) 2016-01-18
JP2016501222A5 true JP2016501222A5 (https=) 2017-01-12
JP6437444B2 JP6437444B2 (ja) 2018-12-12

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545170A Active JP6437444B2 (ja) 2012-11-29 2013-11-26 医薬的組合せ

Country Status (16)

Country Link
US (1) US9446043B2 (https=)
EP (1) EP2925366B1 (https=)
JP (1) JP6437444B2 (https=)
CN (1) CN104812415A (https=)
AU (1) AU2013352379B2 (https=)
BR (1) BR112015012497B1 (https=)
CA (1) CA2892578C (https=)
DK (1) DK2925366T3 (https=)
ES (1) ES2669248T3 (https=)
HU (1) HUE037618T2 (https=)
NZ (1) NZ708802A (https=)
PL (1) PL2925366T3 (https=)
RU (1) RU2674995C2 (https=)
TR (1) TR201806682T4 (https=)
UA (1) UA115250C2 (https=)
WO (1) WO2014085381A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
EP4322953A4 (en) * 2021-04-15 2025-01-22 Ideaya Biosciences, Inc. COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor
GB202408598D0 (en) * 2024-06-14 2024-07-31 Edvince Ab Combination treatments
GB202408599D0 (en) * 2024-06-14 2024-07-31 Vasopharma Ab Combination treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
CA2179650C (en) 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
EP2070921A1 (en) * 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
MX2008000463A (es) 2005-07-11 2008-03-11 Novartis Ag Derivados de indolil-maleimida.

Similar Documents

Publication Publication Date Title
JP2016501222A5 (https=)
Manic et al. Chloroquine and hydroxychloroquine for cancer therapy
Park et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01)
KR102418765B1 (ko) 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
Bullard Dunn et al. Evolving therapies and FAK inhibitors for the treatment of cancer
JP2017502017A5 (https=)
JP2015523397A5 (https=)
JP2018109022A5 (https=)
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
CN105849110A (zh) 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法
JP2014525454A5 (https=)
JP2015526410A5 (https=)
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JP2014509657A5 (https=)
JP2006512324A5 (https=)
JP2012236857A5 (https=)
RU2015124954A (ru) Фармацевтические комбинации
JP2023533464A5 (https=)
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
WO2019058348A1 (en) COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
CN102647986A (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
JP2022544485A (ja) Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置